Edition:
United Kingdom

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

35.70EUR
23 May 2018
Change (% chg)

€-0.20 (-0.56%)
Prev Close
€35.90
Open
€35.90
Day's High
€36.00
Day's Low
€33.55
Volume
248,905
Avg. Vol
127,615
52-wk High
€39.35
52-wk Low
€8.41

Select another date:

Thu, May 3 2018

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* ‍MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA​

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* ‍MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®​

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* ‍MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY​

BRIEF-Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic

* MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC

BRIEF-Mithra Pharmaceuticals Announces Injectables Agreement With GSP

* MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES

Select another date: